9.176EUR+5.40%Mkt Cap: 6.19B EURP/E: 14.90Last update: 2026-05-14
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates thr…
Industry Peers
Drug Manufacturers - Generalloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)14.90
P/E (Forward)8.00
PEG0.24
P/B1.17
P/S0.83
EV/EBITDA10.47
EV/Revenue2.36
EPS (TTM)0.61
EPS (Forward)1.14
Cash Flow & Leverage
FCF Yield14.34%
FCF Margin11.93%
Operating CF1.05B EUR
CapEx (TTM)423.00M EUR
Net Debt/EBITDA5.35
Net Debt8.97B EUR
Technical
SMA 509.166 (+0.1%)
SMA 20010.84 (-15.4%)
Beta1.17
S&P 52W Chg24.23%
Avg Vol (30d)2.63M
Avg Vol (10d)2.48M
Technical Indicators
RSI (14)52.5
MACD-0.1021
MACD Signal-0.1133
MACD Hist.+0.0112
BB Upper9.538 EUR
BB Middle9.059 EUR
BB Lower8.579 EUR
BB Width10.60%
ATR (14)0.2926 EUR
Vol Ratio (20d)0.78x
52W Range
8.43214% of range13.70
52W High13.70 EUR
52W Low8.432 EUR
Profitability
Gross Margin38.00%
EBITDA Margin22.54%
Profit Margin5.34%
Oper. Margin16.47%
ROE7.63%
ROA2.04%
Revenue Growth-4.80%
Earnings Growth—
Balance Sheet
Debt/Equity1.81
Current Ratio2.47
Quick Ratio0.78
Book Value/Sh7.745 EUR
Cash/Share1.031 EUR
Dividends
Fwd Div Rate0.1500 EUR
Trail. Div Rate0.0000 EUR
Div. Yield1.65%
5Y Avg Yield1.48%
Payout Ratio24.63%
Ex-Div DateAug 11, 2025
Pay Date—
Splits
Last Split2:1
Split DateJan 4, 2016
Ownership
Shares Out.422.35M
Float417.32M
Insiders31.87%
Institutions33.91%
Analyst Consensus
Rating2.1 (Buy)
Target (Mean)14.65 EUR
Target Range9.000 EUR – 21.20 EUR
# Analysts12
Company
Market Cap6.19B EUR
Enterprise Value17.54B EUR
Revenue (TTM)7.44B EUR
Gross Profit2.86B EUR
Net Income (TTM)402.00M EUR
Revenue/Share10.93 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees25.0K
Last Price9.176 EUR
CountryES
SectorHealthcare
IndustryDrug Manufacturers - General
ISIN—